Integrated Personalized Diabetes Management (iPDM), strives to address this problem. It is a therapeutic approach which structures the treatment process, connects HCPs and patients, and integrates digital tools that visualize and analyze data. The PDM ProValue study program demonstrates the success of the programme. Patients who were treated for twelve months according to a pre-defined iPDM process achieved significantly better outcomes compared to a control group treated with usual care.
Integrated Personalised Diabetes Management Goes Europe (iPDM-GO) intends to test iPDM in a Danish community setting. The vision of the multi-disciplinary consortium of partners from industry, academia and healthcare administration in Germany and Denmark is to develop and implement a digitally enabled, person-centered care process for people with type 2 diabetes focusing on improving outcomes that matter to patients, and contributing to the sustainability of healthcare systems. Collectively, the team has extensive expertise and skills in clinical practice, computer science, health psychology, health economics, bioinformatics and close-to-market clinical research and development.
In a first step the consortium will develop a digital patient assessment tool that considers a patient’s unique needs and facilitates shared decision-making.
By embedding the tool as a component of an enhanced iPDM process, iPDM-GO aims to add value for patients, HCPs and societies by increasing the effectiveness of care and reducing avoidable hospitalisations. In parallel, the consortium will also use machine learning to leverage existing data from a large patient cohort and develop predictive models that enhance iPDM adaptability, scalability and cost-effectiveness.
The project also aims to lay the groundwork for expanding iPDM-GO to additional European countries and tailoring the solutions to diverse healthcare systems. Here, iPDM-GO calls for a paradigm shift towards value-based healthcare models.
Aligned with the EIT Health guidelines iPDM-GO’s business creation activities aim at the commercialization of the developed patient assessment tool within Roche’s iPDM offering and at the implementation of value-based healthcare.